Likewise, through the immunostaining analysis of tissue samples from HER2+ BC patients, we found that elevated RALA immunohistochemical staining was associated with worse overall survival in this subtype, matching our previous results in a TNBC cohort [30]. The gene discussed is ERBB2; the disease is breast cancer.